Growing community of inventors

Paris, France

Dominique Le Guludec

Average Co-Inventor Count = 5.46

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Dominique Le GuludecSylvie Bay (1 patent)Dominique Le GuludecGiuseppina Caligiuri (1 patent)Dominique Le GuludecMartine Jandrot-Perrus (1 patent)Dominique Le GuludecAntonino Nicoletti (1 patent)Dominique Le GuludecPhilippe Billiald (1 patent)Dominique Le GuludecJulien Muzard (1 patent)Dominique Le GuludecAlain Meulemans (1 patent)Dominique Le GuludecJonathan Vigne (1 patent)Dominique Le GuludecLaure Sarda (1 patent)Dominique Le GuludecMartine Jandrot-perrus (0 patent)Dominique Le GuludecDominique Le Guludec (2 patents)Sylvie BaySylvie Bay (14 patents)Giuseppina CaligiuriGiuseppina Caligiuri (8 patents)Martine Jandrot-PerrusMartine Jandrot-Perrus (8 patents)Antonino NicolettiAntonino Nicoletti (8 patents)Philippe BillialdPhilippe Billiald (5 patents)Julien MuzardJulien Muzard (3 patents)Alain MeulemansAlain Meulemans (2 patents)Jonathan VigneJonathan Vigne (1 patent)Laure SardaLaure Sarda (1 patent)Martine Jandrot-perrusMartine Jandrot-perrus (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Institut National De La Sante Et De La Recherche Medicale (2 from 1,745 patents)

2. Centre National De La Recherche Scientifique (1 from 5,094 patents)

3. Institut Pasteur (1 from 870 patents)

4. Assistance Publique-Hopitaux De Paris (1 from 321 patents)

5. Université Paris Diderot-Paris 7 (1 from 109 patents)

6. Université De Paris (1 from 60 patents)

7. Universite Paris 13 - Paris Nord (1 from 4 patents)

8. Inserm (0 patent)


2 patents:

1. 11098124 - CD31as a molecular target for imaging of inflammation

2. 8466258 - Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/6/2026
Loading…